Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9050
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsai, Chin-Shiang-
dc.contributor.authorLu, Po-Liang-
dc.contributor.authorLu, Min-Chi-
dc.contributor.authordkk.-
dc.date.accessioned2024-12-14T06:44:26Z-
dc.date.available2024-12-14T06:44:26Z-
dc.date.issued2024-04-
dc.identifier.issn1684-1182-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9050-
dc.description.abstractBackground: The clinical burden of Clostridioides difficile infections (CDIs) remains substantial globally. This study aimed to investigate the ribotypes (RTs) and antimicrobial susceptibility of C. difficile isolates collected in Taiwan. Methods: C. difficile isolates were prospectively collected from four medical centers in Taiwan from 2019 to 2021. In a reference laboratory, in vitro susceptibility to clindamycin, moxifloxacin, metronidazole, vancomycin, fidaxomicin, and rifaximin were tested, and ribotyping was conducted to determine their genetic diversity. Results: A total of 568 C. difficile isolates were included. Metronidazole resistance was not observed, and the susceptibility rate of vancomycin was 99.5 %. Clindamycin showed poor activity against these isolates, with a resistance rate of 74.8 %. Fidaxomicin exhibited potent activity and 97.4 % of isolates were inhibited at 0.25 mg/mL. Rifaximin MIC90 increased from 0.015 mg/mL in 2019 to 0.03 mg/mL in 2020 and 2021. Of 40 RTs identified, two predominant RTs were RT 078/126 (78, 14 %) and 014/020 (76, 13 %). RT 017, traditional harboring truncated tcdA, accounted for 3 % (20 isolates) and there was no isolate belonging to RT 027. The proportions of RT 078 increased from 11.2 % in 2019 to 17.1 % in 2021, and the predominance of RT 078/126 was more evident in central Taiwan. Conclusions: Vancomycin, fidaxomicin, and metronidazole remain in vitro effective against clinical C. difficile isolates in Taiwan. The reservoirs and genetic relatedness of two major RTs with zoonotic potentials, RT 078/126 and 014/020, warrant further investigations.en_US
dc.language.isoen_USen_US
dc.publisherJournal of Microbiology, Immunology and Infectionen_US
dc.relation.ispartofseriesOriginal Article;320-327-
dc.subjectClostridioides (Clostridium) difficileen_US
dc.subjectRibotypeen_US
dc.subjectAntimicrobial susceptibilityen_US
dc.subjectFidaxomicinen_US
dc.titleRibotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019e2021en_US
dc.typeArticleen_US
Appears in Collections:Vol. 57 No. 2 (2024)

Files in This Item:
File Description SizeFormat 
320-327.pdf1.72 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.